Human trials of Crispr editing are being proposed by Massachusetts-based start-up Editas Medicine to treat a rare form of blindness knwon as Leber congenital amaurosis.
‘Gene repair’ could be tested on people in 2017
Posted in biotech/medical
Posted in biotech/medical
Human trials of Crispr editing are being proposed by Massachusetts-based start-up Editas Medicine to treat a rare form of blindness knwon as Leber congenital amaurosis.